These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22192053)

  • 1. A mini review of nanosuspensions development.
    Liu Y; Xie P; Zhang D; Zhang Q
    J Drug Target; 2012 Apr; 20(3):209-23. PubMed ID: 22192053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats.
    Sigfridsson K; Lundqvist A; Strimfors M
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1832-9. PubMed ID: 23240709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
    Müller RH; Jacobs C; Kayser O
    Adv Drug Deliv Rev; 2001 Mar; 47(1):3-19. PubMed ID: 11251242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of nanosuspensions in drug delivery.
    Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D
    J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18.
    Pardeike J; Müller RH
    Int J Pharm; 2010 May; 391(1-2):322-9. PubMed ID: 20214969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling.
    Ali HS; York P; Ali AM; Blagden N
    J Control Release; 2011 Jan; 149(2):175-81. PubMed ID: 20946923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability.
    Wang Y; Wang C; Zhao J; Ding Y; Li L
    J Colloid Interface Sci; 2017 Jan; 485():91-98. PubMed ID: 27657837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
    Leone F; Cavalli R
    Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies.
    Tian X; Li H; Zhang D; Liu G; Jia L; Zheng D; Shen J; Shen Y; Zhang Q
    Colloids Surf B Biointerfaces; 2013 Aug; 108():29-33. PubMed ID: 23528604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS).
    Friedrich I; Reichl S; Müller-Goymann CC
    Int J Pharm; 2005 Nov; 305(1-2):167-75. PubMed ID: 16242276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of optimized sucrose ester stabilized oleanolic acid nanosuspensions prepared by wet ball milling with design of experiments.
    Li W; Ng KY; Heng PW
    Biol Pharm Bull; 2014; 37(6):926-37. PubMed ID: 24882406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
    Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
    Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
    Freag MS; Elnaggar YS; Abdallah OY
    Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanosuspension formulations of poorly water-soluble compounds for intravenous administration in exploratory toxicity studies: in vitro and in vivo evaluation.
    Fujimura H; Komasaka T; Tomari T; Kitano Y; Takekawa K
    J Appl Toxicol; 2016 Oct; 36(10):1259-67. PubMed ID: 26849104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational Design and Characterization of a Nanosuspension for Intraoral Administration Considering Physiological Conditions.
    Baumgartner R; Teubl BJ; Tetyczka C; Roblegg E
    J Pharm Sci; 2016 Jan; 105(1):257-67. PubMed ID: 26852857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect.
    Chen Y; Liu J; Yang X; Zhao X; Xu H
    J Pharm Pharmacol; 2005 Feb; 57(2):259-64. PubMed ID: 15720792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanocrystal technology, drug delivery and clinical applications.
    Junghanns JU; Müller RH
    Int J Nanomedicine; 2008; 3(3):295-309. PubMed ID: 18990939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanosuspensions of a new compound, ER-β005, for enhanced oral bioavailability and improved analgesic efficacy.
    Ye L; Miao M; Li S; Hao K
    Int J Pharm; 2017 Oct; 531(1):246-256. PubMed ID: 28847666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.